Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Combination Products Join The User Fee Family?

Executive Summary

Joint drug and device negotiations for combination products, separate performance goals, or maybe a separate pathway have been discussed.

Advertisement

Related Content

Combo Products Won't Get Special Review Pathway At US FDA Anytime Soon
PDUFA First: Fees To Support US FDA Device Center Staff
FDA's Combo Products Review Transformation Begins
PDUFA First: Fees To Support Device Center Staff
PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up
For Combination Product Development, Industry Says Talk Is Cheap
CDER-Only Reviews Increase For Combination Products With Stand-Alone Devices, But Issues Remain

Topics

Advertisement
UsernamePublicRestriction

Register

PS056959

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel